Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics

Taimur Sher, Kena C. Miller, David Lawrence, Amy Whitworth, Francisco Hernandez-Ilizaliturri, Myron S. Czuczman, Austin Miller, William Lawrence, Syed Ali Bilgrami, Raman Sood, Margaret T. Wood, Annemarie W. Block, Kelvin Lee, Asher Alban Chanan-Khan

Research output: Contribution to journalArticlepeer-review

77 Scopus citations


Patients with chronic lymphocytic lymphoma (CLL) with high-risk cytogenetics [del(11q)(q22.3) or del(17p)(p13.1)] have limited therapeutic options and their prognosis remains poor. This analysis was conducted to determine the clinical activity of lenalidomide in patients with high-risk disease. Relapsed/refractory patients with CLL enrolled in a phase II clinical trial who had del(11q)(q22.3) or del(17p)(p13.1) were included in this analysis. Patients received single agent lenalidomide for 21 days of the 4 week treatment cycle. The overall response rate among patients with high-risk cytogenetics was 38%, with 19% of patients achieving a complete response. Median progression-free survival was 12.1 months, which is higher than emonstrated with other agents in comparable patient populations. In addition, the estimated 2-year survival probability was 58%, demonstrating that the responses achieved with lenalidomide are durable, even in patients with CLL with high-risk disease with poor risk cytogenetics.

Original languageEnglish (US)
Pages (from-to)85-88
Number of pages4
JournalLeukemia and Lymphoma
Issue number1
StatePublished - Jan 2010


  • Chronic lymphocytic leukemia
  • Fludarabine-refractory
  • High-risk cytogenetics
  • Lenalidomide

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics'. Together they form a unique fingerprint.

Cite this